In Alzheimer’s disease, the levels of plasma lysosomal enzymes vary depending on disease progression and are more sensitive to cellular metabolic alteration compared to the levels of amyloid-β peptide or tau proteins18. This evidence concerns the gene MAPT and Alzheimer disease.